|

L-NMMA Clinical Trials

1 actively recruiting trial across 1 location

Also known as: iNOS inhibitor

Pipeline

Phase 2: 1

Top Sponsors

  • The Methodist Hospital Research Institute1

Indications

  • Metaplastic Breast Carcinoma1
  • TNBC - Triple-Negative Breast Cancer1
  • Metastatic Breast Cancer1
  • HER2-negative Breast Cancer1
  • Breast Cancer1

Bethesda, Maryland1 trial

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

National Institute of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.